Related Experiment Videos
Antithrombotic therapy after coronary stent placement
A Marzocchi1, G Piovaccari, C Marrozzini
1Istituto di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Bologna.
Insights
Acetylsalicylic acid (ASA) plus ticlopidine significantly reduced subacute stent thrombosis and bleeding complications compared to ASA plus warfarin after coronary stenting. This combination offers improved outcomes for patients undergoing stent procedures.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Subacute stent thrombosis and bleeding complications are significant limitations following coronary stenting.
- Current antithrombotic therapy after coronary stent placement lacks standardization.
- Intensive anticoagulant therapy, such as warfarin, poses risks of hemorrhagic complications.
Purpose of the Study:
- To compare the efficacy and safety of two antithrombotic regimens following Palmaz-Schatz coronary stent implantation.
- To evaluate the incidence of subacute stent thrombosis and major bleeding complications between treatment groups.
Main Methods:
- A total of 338 Palmaz-Schatz stents were implanted in 285 patients between January 1994 and December 1995.
- Group A (135 patients) received acetylsalicylic acid (ASA) and warfarin, with intravenous heparin bridging.
- Group B (146 patients) received ASA plus ticlopidine, with subcutaneous heparin post-procedure.
Main Results:
- Subacute stent thrombosis occurred in 3.9% of patients (9 in Group A vs. 2 in Group B; p = 0.04).
- Major bleeding complications were observed in 6 patients in Group A versus 2 in Group B.
- The ASA plus ticlopidine group demonstrated a statistically significant reduction in both cardiac events and bleeding.
Conclusions:
- Antithrombotic therapy with acetylsalicylic acid (ASA) plus ticlopidine is superior to ASA plus warfarin in reducing subacute stent thrombosis after coronary stenting.
- The ASA plus ticlopidine regimen also significantly decreases major hemorrhagic complications.
- This combination therapy offers improved clinical benefits and safety profiles for patients receiving coronary stents.
Abstract:
Subacute stent thrombosis and hemorrhagic complications due to intensive anticoagulant therapy limit the clinical benefit of coronary stenting. Antithrombotic therapy after coronary stent placement has not been standardized yet. From January 1994 to December 1995 a total of 338 Palmaz-Schatz stents were implanted in 285 patients. Procedural success rate was 98.8%. In the initial period, after stent placement, patients were treated with acetylsalicylic acid (ASA) and warfarin (135 patients, Group A), while subsequently, according to the results of other studies, patients were treated with ASA plus ticlopidine (146 patients, Group B). Two hours after sheath removal, Group A patients were treated with intravenous heparin until therapeutic INR (2.5-3.5) was reached; warfarin was stopped 3 months later. In Group B patients 2 hours after sheath removal a treatment with subcutaneous heparin 25,000 IU/die plus ticlopidine 500 mg/die was started. Subcutaneous heparin was maintained until hospital discharge, ticlopidine was stopped after 1 month and ASA was maintained indefinitely. There were no significant differences in baseline characteristics between the two groups. Most patients had unstable angina and in the majority of cases the stent was implanted due to intimal dissection after balloon dilation. Eleven patients had subacute thrombosis of the stent (3.9%): 9 patients were in Group A (6%) and 2 patients were in Group B (1.3%; p = 0.04). Seven patients (6 in Group A, 1 in Group B) were treated with emergency coronary angioplasty and 3 (2 in Group A, 1 in Group B) with coronary bypass; nevertheless 7 patients (6 in Group A, 1 in Group B) had an acute myocardial infarction. Eight patients (6 in Group A, 2 in Group B) had major bleeding due to a large groin hematoma requiring blood transfusion or vascular surgery. In conclusion, after coronary stenting antithrombotic therapy with ASA plus ticlopidine, as compared with anticoagulant therapy, reduces the incidence of both cardiac events and hemorrhagic complications.